Global Salivary Gland Cancer Market Overview:
Salivary gland cancer is an erratic disease in which cancer cells form in the tissues of the salivary glands. Most salivary gland tumors are benign and arise in the parotid glands. A painless salivary mass is the most general sign and is evaluated by fine-needle aspiration biopsy. Increasing incidence of salivary gland cancer is major driver for the market while other factors like increasing awareness about this disorder, the introduction of the new treatment or therapies and increasing demand from emerging markets drives the growth of the global market Some of the key players profiled in the study are Bayer AG (Germany), Johnson & Johnson (United States), Loxo Oncology, Inc. (United States), Merck & Co., Inc. (United States), Plexxikon Inc. (United States), Taiwan Liposome Company, Ltd. (Taiwan), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Co (United States), AstraZeneca Plc (United Kingdom) and Novartis AG (Switzerland).
On the basis of geography, the market of Salivary Gland Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Asia Pacific on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Treatment, the sub-segment i.e. Surgery will boost the Salivary Gland Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Physical exam will boost the Salivary Gland Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing cases of salivary gland cancer
- Growing awareness among the patients and rapidly improving healthcare infrastructure
- The introduction of the new treatment or therapies
- Increasing use of insurance facilities
- Lack of awareness about disorder
- Rising demand from emerging markets
- Limited availability of required healthcare facilities
On 14 Dec, 2018, Merck [NYSE:MRK], known as MSD outside the United States and Canada, and privately held Antelliq Group today announced that the companies have signed a definitive agreement under which Merck will acquire Antelliq
The Federal Food, Drug, and Cosmetic Act is the basic food and drug law of the U.S. With numerous amendments, it is the most extensive law of its kind in the world. The law is intended to assure the consumer that foods are pure and wholesome, safe to eat, and produced under sanitary conditions; that drugs and devices are safe and effective for their intended uses; that cosmetics are safe and made from appropriate ingredients; and that all labeling and packaging is truthful, informative, and not deceptive
Target Audience:Salivary Gland Cancer Diagnostic and Treatment Supplies Companies, Salivary Gland Cancer Diagnostic and Treatment Supplies Providers, Medical Research Laboratories, Research and Development (R&D) Companies, Market Research and Consulting Service Providers and Potential Investors
Major Objectives Focused through this Study To define, describe, and forecast the Global Salivary Gland Cancer market on the basis of product [Parotid glands, Submandibular glands and Sublingual glands] , application [Hospitals & clinics, Medical research centers, Academic institutes and Others], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Salivary Gland Cancer market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Salivary Gland Cancer industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization: Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Pfizer Inc (United States), Daiichi Sankyo Co (Japan) and Astellas Pharma Inc (Japan).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Salivary Gland Cancer market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.